Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience, Inc. has issued a preliminary proxy for its virtual 2025 Annual Meeting to be held October 31, 2025. The Board recommends five proposals: elect two Class II directors to three-year terms ending 2028; ratify Marcum as independent auditor for fiscal 2025; approve Amendment No. 1 to the equity incentive plan to add 317,820 shares and provide annual automatic increases (up to 4% of outstanding shares) from January 1, 2026 through January 1, 2035; authorize the Board to increase authorized shares from 101,000,000 to up to 5,001,000,000 (including 1,000,000 preferred); and permit adjournment if needed to solicit votes. The proxy discloses board composition, committee charters, related-person transaction review procedures, indemnification and insurance, and executive compensation summary including pay-versus-performance tables and narrative. Proxy materials and the 2024 Form 10-K are available at the links provided.